Ashley Wood, ATC in Galt, CA - Preventive Medicine

Ashley Wood, ATC is a Preventive Medicine - Sports Medicine physician based in Galt, California. Ashley Wood is licensed to practice in California (license number BOC270768) and her current practice location is 12945 Marengo Rd, Galt, California. She can be reached at her office (for appointments etc.) via phone at (209) 744-4250.

NPI number for Ashley Wood is 1982242434 and her current mailing address is 12945 Marengo Rd, Galt, California. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1982242434.

Contact Information

	Ashley Wood, ATC
	12945 Marengo Rd, Galt, CA 95632-8422
	(209) 744-4250
	Not Available

Physician's Profile

Full Name	Ashley Wood
Gender	Female
Speciality	Preventive Medicine - Sports Medicine
Location	12945 Marengo Rd, Galt, California
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1982242434
Provider Enumeration Date: 12/16/2019
Last Update Date: 12/16/2019

Medical Identifiers

Medical identifiers for Ashley Wood such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1982242434	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2083S0010X	Preventive Medicine - Sports Medicine	BOC270768 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ashley Wood is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ashley Wood, ATC 12945 Marengo Rd, Galt, CA 95632-8422 Ph: () -	Ashley Wood, ATC 12945 Marengo Rd, Galt, CA 95632-8422 Ph: (209) 744-4250

News Archive

Osiris Therapeutics receives $15 million cash payment from Mesoblast for Prochymal

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it has received the next $15 million cash payment from Mesoblast in accordance with the Purchase Agreement relating to the Prochymal business.

Organizations highlight plight of HIV-positive Haitians, call for donors to support 'whole of society' health system strengthening

Organizations attending the International AIDS Conference-AIDS 2010 highlighted the plight of HIV-positive earthquake survivors in Haiti who are "still waiting for aid promised to them before" the quake as rebuilding efforts slowly move along, Agence France-Presse reports.

Kidney treatment could affect mouth health

Study results indicate a positive association between the type of treatment modality chronic kidney disease patients receive and the likelihood for them having periodontitis.

New molecule blocks lymphangiogenesis

Researchers in the laboratory of Dr. Jayakrishna Ambati at the University of Kentucky have discovered the first naturally occurring molecule that selectively blocks lymphatic vessel growth. In an article in the Aug. 9, 2009 online edition of Nature Medicine, they report the identification of a new molecule known as soluble VEGFR-2 that blocks lymphangiogenesis - the growth of lymphatics - but not blood vessel growth.

India will continue to produce generic HIV drugs, Commerce and Industry Minister says

"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.

Ashley Wood, ATC - Preventive Medicine in Galt, CA